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……………………………………………………….......2 Supplementary Table S2 Wilcoxon signed-rank test were used. A p value of <0.05 was considered statistically significant. Supplementary Figure S7 . Dose dependently changes of soluble immune checkpoint protein levels following sorafenib treatment. Graphs showed the fold changes of sBTLA, sPD-1, sPD-L1, sCD80, sTLR-2 and sICOS levels in patients who received an initial dose of sorafenib (800 mg) and in patients with immediate dose reduction (to 400 mg) at baseline and at week 1, 2, and 4 of treatment.
